Hepatitis C Virus Donor Positive Kidney Transplantation for Hepatitis C Virus Negative Recipients
Status:
Completed
Trial end date:
2020-03-15
Target enrollment:
Participant gender:
Summary
The development of direct acting anti-virals (DAAs) for the treatment of Hepatitis C virus
(HCV) has changed the landscape of HCV therapy dramatically in the last several years with
reported sustained virologic response (SVR) rates in excess of 95% for treatment-naïve HCV
positive patients including those who have received liver or kidney transplants. Since these
new regimens do not include interferon and have already been studied in the post-liver and
kidney transplant setting, they now offer a unique opportunity to expand the donor pool and
improve the lives of those awaiting renal transplant. The address this gap in knowledge, the
investigators hypothesize that pre-emptive treatment with a direct acting anti-viral HCV
medication to cure HCV soon after transplant would allow for safe transplantation of HCV
positive kidneys in disadvantaged and needy HCV negative kidney recipients with acceptable
risks and improved survivals compared with historical cohorts.
Phase:
Early Phase 1
Details
Lead Sponsor:
Virginia Commonwealth University
Treatments:
Antiviral Agents Elbasvir-grazoprevir drug combination Sofosbuvir Sofosbuvir-velpatasvir drug combination